Menu Search
Equities

Lexeo Therapeutics Inc

LXEO:NMQ

Lexeo Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.78
  • Today's Change0.36 / 3.45%
  • Shares traded2.47m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Lexeo Therapeutics Inc's revenues fell -100.00% from 654.00k to 0.00. has fallen 12.01% from a loss of 59.28m to a larger loss of 66.39m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-60.10%
Return on equity-724.04%
Return on investment-68.82%
More ▼

Cash flow in USDView more

In 2023, Lexeo Therapeutics Inc increased its cash reserves by 54.76%, or 44.13m. Cash Flow from Financing totalled 103.79m or -- of revenues. In addition the company used 59.50m for operations while cash used for investing totalled 165.00k.
Cash flow per share-2.78
Price/Cash flow per share--
Book value per share4.99
Tangible book value per share4.99
More ▼

Balance sheet in USDView more

Lexeo Therapeutics Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio9.38
Quick ratio--
Total debt/total equity0.0098
Total debt/total capital0.0097
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.